You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Objective Response

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Objective Response, Overall Survival Trial in Beijing (VIA combination treatment)

Completed
  • Objective Response
  • Overall Survival
  • VIA combination treatment
  • Beijing, China
    Peking University People's Hospital
Dec 9, 2022

Objective Response Rate Trial in Wuhan (GM-CSF)

Recruiting
  • Objective Response Rate
  • Wuhan, Hubei, China
    Renmin Hospital of Wuhan University
Feb 25, 2023

Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))

Recruiting
  • Advanced Breast Cancer
  • +2 more
  • Trastuzumab Emtansine (T-DM1)
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023

Objective Response Rate (ORR) Trial (Envafolimab, Lenvatinib Combined With TACE)

Not yet recruiting
  • Objective Response Rate (ORR)
  • Envafolimab, Lenvatinib Combined With TACE
  • (no location specified)
Oct 13, 2022

Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality

Recruiting
  • Breast Cancer Stage IV
  • comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
  • Mansoura, Dakahlia, Egypt
    Oncology center mansoura university
Jan 1, 2023

Cancer, Melanoma Trial in Worldwide (Dabrafenib, Trametinib)

Completed
Has Results
  • Cancer
  • Melanoma
  • Guangzhou, Guangdong, China
  • +12 more
Jan 4, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus

Recruiting
  • Recurrent Cervical Carcinoma
  • +9 more
  • Tislelizumab plus radiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Primary CNS Lymphoma Trial in Milan (Lumbar puncture)

Recruiting
  • Primary CNS Lymphoma
  • Lumbar puncture
  • Milan, Italy/Lombardy, Italy
    IRCCS Ospedale San Raffaele
Sep 5, 2021

Breast Cancer Trial in Nanjing (Pyrotinib, Trastuzumab, Pertuzumab)

Recruiting
  • Breast Cancer
  • Nanjing, Jiangsu, China
    the First Affiliated Hospital of Nanjing Medical University
Jun 2, 2021

Optimisation of Hearing Aid Fitting

Completed
  • Hearing Loss
  • Hearing Abnormality
  • Objective speech response detection
  • Reading, Berkshire, United Kingdom
    Royal Berkshire NHS Foundation Trust
Jul 24, 2021

Anesthesia, Pain, Acute Trial in Gothenburg (NoL)

Recruiting
  • Anesthesia
  • Pain, Acute
  • NoL
  • Gothenburg, Sweden
    Sahlgrenska University hospital
Jan 11, 2022

Fasting Mimicking Diet, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer Trial in Netherlands (Fasting

Not yet recruiting
  • Fasting Mimicking Diet
  • +5 more
  • Fasting Mimicking diet program
  • Alkmaar, Netherlands
  • +14 more
Aug 15, 2022

Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score Trial in France

Not yet recruiting
  • Metastatic Renal Cell Carcinoma
  • Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
  • Combination PD-1/PD-L1 ICI + VEGFR-TKI
  • Treatment pause
  • Bayonne, France
  • +24 more
Aug 10, 2022

Interstitial Cystitis, Painful Bladder Syndrome Trial (bupivacaine, triamcinolone, and heparin (BTH), dimethyl sulfoxide (DMSO))

Completed
  • Interstitial Cystitis
  • Painful Bladder Syndrome
  • bupivacaine, triamcinolone, and heparin (BTH)
  • dimethyl sulfoxide (DMSO)
  • (no location specified)
Jan 24, 2022

Objective Response Rate Trial in Jinan (albumin-bound paclitaxe combined with bevacizumab biosimilar)

Recruiting
  • Objective Response Rate
  • albumin-bound paclitaxe combined with bevacizumab biosimilar
  • Jinan, Shandong, China
    Qilu Hospital of Shandong University
Oct 7, 2021

Objective Response Rate Trial in Hangzhou (CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine)

Recruiting
  • Objective Response Rate
  • CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 5, 2021

Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor Trial in Beijing (Combination of nimotuzumab and

Recruiting
  • Recurrent Cervical Carcinoma
  • +6 more
  • Combination of nimotuzumab and radiotherapy
  • Beijing, Beijing, China
    Lei Li
Dec 18, 2020

Chemo, Anti-pd-1 Antibody, Cervical Neuroendocrine Carcinoma Trial in Beijing (Drug therapy)

Recruiting
  • Chemotherapy
  • +6 more
  • Drug therapy
  • Beijing, Beijing, China
    Lei Li
Nov 15, 2020

Heart Failure, ICD, Chronotropic Incompetence Trial in La Jolla (CLS Mode on Biotronik CRT-D, Accelerometer Mode on Biotronik

Completed
Has Results
  • Heart Failure
  • +2 more
  • CLS Mode on Biotronik CRT-D
  • Accelerometer Mode on Biotronik CRT-D
  • La Jolla, California
    Sulpizio Cardiovascular Center
Jul 14, 2021

Unresected Stage IIIb to IVM1c Melanoma Trial in Worldwide (Talimogene Laherparepvec)

Completed
Has Results
  • Unresected Stage IIIb to IVM1c Melanoma
  • Talimogene Laherparepvec
  • Salt Lake City, Utah
  • +41 more
Nov 26, 2021

MDS Trial in Worldwide (Oral Azacitidine, Durvalumab)

Active, not recruiting
Has Results
  • Myelodysplastic Syndromes
  • New Haven, Connecticut
  • +65 more
Aug 19, 2022

Castration Resistant Metastatic Prostate Cancer Trial in United States (Testosterone cypionate, Enzalutamide, Testosterone

Completed
Has Results
  • Castration Resistant Metastatic Prostate Cancer
  • Testosterone cypionate
  • +2 more
  • Birmingham, Alabama
  • +16 more
Oct 9, 2020

Pseudotumor Cerebri Trial in Tel HaShomer (objective chromatic multifocal pupillometer)

Unknown status
  • Pseudotumor Cerebri
  • objective chromatic multifocal pupillometer
  • Tel HaShomer, Israel
    Sheba Medical Center
Mar 19, 2020

Peripheral T-cell Lymphoma Trial in Worldwide (Pralatrexate Injection)

Terminated
Has Results
  • Peripheral T-cell Lymphoma
  • Pralatrexate Injection
  • Novi, Michigan
  • +54 more
Nov 18, 2021

Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Relapsed Refractory Multiple Myeloma
  • (no location specified)
Feb 6, 2023